Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Demcizumab |
Synonyms | |
Therapy Description |
Demcizumab (OMP-21M18) is a monoclonal antibody that binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation and tumor growth (PMID: 19664991, PMID: 25324140, PMID: 32037195). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Demcizumab | OMP-21M18|anti-delta-like 4 monoclonal antibody OMP-21M18 | DLL4 Antibody 7 | Demcizumab (OMP-21M18) is a monoclonal antibody that binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation and tumor growth (PMID: 19664991, PMID: 25324140, PMID: 32037195). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01952249 | Phase Ib/II | Demcizumab Paclitaxel | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | Terminated | USA | 0 |
NCT02259582 | Phase II | Carboplatin + Pemetrexed Disodium Demcizumab | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | ITA | ESP | BEL | AUS | 0 |